Sign In
×Brief
Company Status: | Listed |
Business Activity: | Developing, manufacturing and marketing pharmaceuticals. |
Current Capital: | 700.00 Million Riyal |
Current No. of Shares (M) (M): |
IPO Facts
Issue Type: | IPO |
Status: | Listed |
Exchange Market: | TASI |
Sector: | Health care |
Country: | Saudi Arabia |
Offered Shares (M): | |
Offered Percentage: | 30.00 % |
Offer Price (Riyal): | 60.00 |
Issue Volume (M Riyal): | 1,260.00 |
Premium: | 50.00 Riyal |
Available Shares (Individual): | |
Minimum Subscription (Individuals): | |
Maximum Subscription (Individuals): | 250.00 Thousand Shares |
Available Shares (Institutions): | 18.90 Million Shares |
Minimum Subscription (Institutions): | 100.00 Thousand Shares |
Maximum Subscription (Institutions): | 3.50 Million Shares |
Eligibility : | _ Participating Parties, _ Individual Investors . |
Use of Proceeds: | The Net Proceeds from the Offering amounting to approximately SAR 1260 million (after deducting the Offering expenses estimated at SAR 51.5 million) will be distributed to the Selling Shareholders based on each Selling Shareholder’s percentage ownership in the Offer Shares, The Company will not receive any part of the Net Proceeds from the Offerin . |
Restrictions on Dealing in Shares: | The Substantial Shareholder, will be subject to a Lock-up Period of six (6) months starting from the commencement of trading of the Shares on the Saudi Stock Exchange, during which the Substantial Shareholder shall be prohibited from disposing of its Shares, In addition, the Company is prohibited from listing shares of the same class as the Offer Shares for a period of 6 months starting from the start of trading of the Offer Shares on the Exchange . |
Prospectus: | Downloads |
: | Downloads |
Key Dates
Capital Market Authority Approval: | 12/28/2022 |
The minimum & maximum offering price: | 5/30/2023 |
Subscription End Date: | 6/1/2023 |
Allocation Date: | 6/7/2023 |
Distribution Date: | 6/11/2023 |
Listing Date: | 6/20/2023 |
Major Shareholders
Name | No. of Shares | Holding | Value |
---|---|---|---|
Youssef Mohamed Saleh Jamjoom | 29.16 | 41.65 % | 4,075.87 |
Mahmoud Youssef Muhammad Salih Jamjoom | 3.92 | 5.60 % | 548.02 |
Advisors
Lead Manager: | Saudi Fransi Capital |
Underwriter: | J.P. Morgan Saudi Arabia Co., Saudi Fransi Capital , Al Rajhi Capital Company |
Financial Advisor: | J.P. Morgan Saudi Arabia Co., Saudi Fransi Capital |
Legal Advisor: | Baker & McKenzie Limited, The Law Office of Megren M. Al-Shaalan , White & Case LLP |
Auditor: | KPMG Consulting Co. |
Receiving Bank: | The Saudi National Bank, Banque Saudi Fransi, Al Rajhi Bank |
IPO results
Proceeds: | SAR 1.39 billion |
Subscription Percentage: | 1100% |
No. of Subscribers: | 170.52 thousand subscribers |
Allocation: | 4 shares per individual subscriber & The remaining shares will be allocated on a pro rata basis at around 0.5146% on average . |
Chart - Jamjoom Pharmaceuticals Factory Co.
Share Performance
Last Price: | 139.80 |
Change: | 1.01 % |
Market Cap (M): | 9,800.00 |
Turnover: | 108,093,463.00 |
Transactions: | 5,431.00 |
Share Stats
First Day Open: | 85.80 |
First Day High: | 92.80 |
First Day Low: | 85.80 |
First Day Close: | 90.30 |
1st Day Change: | 50.50 % |
1st Month Change: | 114.33 % |
1st year Change: | - |
Since listing: | 133.33 % |
Related News
Jamjoom Pharma to debut on Tadawul todayArgaam Special20/06/2023
Jamjoom Pharma shares to debut on Tadawul on June 20Argaam18/06/2023
Retail subscription to 2.1 mln shares of Jamjoom Pharma IPO starts todayArgaam Special30/05/2023
Here’s a list of receiving banks for Jamjoon Pharma IPOArgaam30/05/2023
Jamjoom Pharma sets IPO final price at SAR 60/shareArgaam25/05/2023
Jamjoom Pharma sets IPO price range between 56-60/share Argaam15/05/2023
Call Request